RxDoctor Payments DataLook up a doctor →

Bradley Priebe, DO

Neurology · Colorado Springs, CONPI 1609195676

Payments from drug & device makers

$105,182in general payments, 2019–2025

Across 1,335 payments — averaging $78.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$60K
  • Pfizer$9K
  • Lilly USA, LLC$9K
  • Novartis$7K
  • UCB, Inc.$2K
  • Boston Scientific$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$9,72510%
  • Speaking & faculty fees$61,66762%
  • Travel & lodging$2,0492%
  • Food & beverage$26,53026%
  • Education$2120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)233$60,165
Pfizer102$9,307
Lilly USA, LLC29$9,208
Novartis94$6,548
UCB, Inc.60$1,701
Boston Scientific12$1,476
TG Therapeutics, Inc.47$1,471
AstraZeneca(2 entities)55$1,242
EMD Serono, Inc.53$1,068
SK Life Science, Inc.40$906
MDD US Operations, LLC33$858
Biogen45$849
Amgen(2 entities)44$822
Neurocrine Biosciences, Inc.44$790
Genentech USA, Inc.24$581
Acadia Pharmaceuticals Inc39$567
Lundbeck LLC29$559
Abbott15$507
Mallinckrodt Hospital Products Inc.18$376
Sanofi20$374
Neurelis, Inc.15$370
Bristol Myers Squibb22$368
Argenx US, Inc.19$335
Tanabe Pharma America, Inc.18$334
Catalyst Pharmaceuticals, Inc.15$320
Amneal Pharmaceuticals LLC12$252
Grifols USA, LLC12$241
Teva Pharmaceuticals USA, Inc.12$234
Eisai Inc.12$230
Alnylam Pharmaceuticals Inc.11$215
Biohaven Pharmaceutical Holding Company Ltd.11$214
Biohaven Pharmaceuticals, Inc.11$207
Merz Pharmaceuticals, LLC8$177
Sunovion Pharmaceuticals Inc.10$159
Livanova USA, Inc.8$133
Mallinckrodt Enterprises LLC11$128
Johnson & Johnson(2 entities)6$123
Vanda Pharmaceuticals Inc.4$121
Jazz Pharmaceuticals Inc.5$111
Acorda Therapeutics, Inc5$105
ANI Pharmaceuticals, Inc.4$91
Kyowa Kirin, Inc.4$89
Otsuka America Pharmaceutical, Inc.4$88
CSL Behring4$88
Cycle Pharmaceuticals Inc4$85
Akcea Therapeutics, Inc.4$76
Amylyx Pharmaceuticals, Inc.3$66
Merz North America, Inc.3$61
Avion Pharmaceuticals4$60
Harmony Biosciences LLC2$56
Impel Pharmaceuticals Inc.3$54
Adamas Pharmaceuticals, Inc.3$50
Medtronic2$47
Collegium Pharmaceutical, Inc.3$47
Banner Life Sciences, LLC3$44
Octapharma USA, Inc.2$42
Springworks Therapeutics, Inc.2$41
GRT US Holding, Inc.2$35
Supernus Pharmaceuticals, Inc.2$35
E.r. Squibb & Sons, L.L.C.2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,182 in reported general payments places this provider in the 80th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$492,098
Medicare patients
552
Services billed
28,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5035$328,335
RytaryCarbidopa/Levodopa198$237,596
Droxidopa25$165,392
IngrezzaValbenazine Tosylate21$157,090
NuplazidPimavanserin Tartrate21$145,527
AustedoDeutetrabenazine18$93,184
BotoxOnabotulinumtoxina42$55,392
QuliptaAtogepant40$46,921
Aimovig AutoinjectorErenumab-Aooe40$32,431
BriviactBrivaracetam23$32,185
Lacosamide84$23,030
Ajovy AutoinjectorFremanezumab-Vfrm21$20,988
AptiomEslicarbazepine Acetate16$20,942
Nurtec OdtRimegepant Sulfate13$17,740
Carbidopa-LevodopaCarbidopa/Levodopa391$14,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$252$241,242242 claims
Neurocrine Biosciences, Inc.Ingrezza$790$157,09021 claims
Acadia Pharmaceuticals IncNuplazid$567$145,52721 claims
AbbVieBotox, Qulipta$60,165$102,31382 claims
Teva Pharmaceuticals USA, Inc.Austedo$234$93,18418 claims
UCB, Inc.Briviact$1,701$32,18523 claims
Sunovion Pharmaceuticals Inc.Aptiom$159$20,94216 claims
PfizerNurtec Odt$9,307$17,74013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 334 neurology providers in Colorado.

Other neurology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →